Arnold Milstein MD Arnold Milstein MD Alan Ezekowitz Charles G. Hadley,General Partner    

Jonathan Bush

Arnold Milstein

Paul Schimmel

Alan Ezekowitz

Charles G. Hadley

Paul Schimmel is Ernest and Jean Hahn Professor at The Skaggs Institute for Chemical Biology at The Scripps Research Institute. He formerly was the John D. and Catherine T. MacArthur Professor of Biochemistry and Biophysics in the Department of Biology at MIT. Schimmel is author or co-author of more than 450 scientific papers and of a widely used three volume textbook on biophysical chemistry. For his achievements and discoveries in scientific research in the biological sciences, Schimmel has been honored as an elected member of the American Academy of Arts and Sciences, the National Academy of Sciences, the American Philosophical Society, and the Institute of Medicine. Additional honors, among others, related to research and educational achievements include the American Chemical Society’s Pfizer Award in Enzyme Chemistry, the Stein and Moore Award (the highest honor of The Protein Society), the Biophysical Society’s Emily M. Gray Award (co-recipient) for significant contributions to education in biophysics,

the Chinese Biopharmaceutical Society’s Brilliant Achievement Award, the Perlman Award (Lecture) of the American Chemical Society, and the Nucleic Acids Award (Lecture) of the Biochemical Society and Royal Society of Chemistry, UK. He has been active in many scientific and academic organizations and committees, including service as Chairman of the Division of Biological Chemistry of the American Chemical Society and as an editorial board member of ten different scientific journals.

Having a longstanding interest in the applications of basic biomedical research to human health, Schimmel holds numerous patents and is a cofounder or founding director of several biotechnology companies, of which six (Alkermes, Inc., Alnylam Pharmaceuticals, Inc., Sirtris Pharmaceuticals (sold to Glaxo in 2008), Cubist Pharmaceuticals, Inc., Momenta Pharmaceuticals, Inc., Repligen Corporation) became publicly traded. These companies are developing new therapies for human diseases and disorders.